Insights

ISPOR Europe 2019

Several members of leadership team will be joining the discussion with global healthcare leaders at ISPOR Europe

Conferences

ClearView Poster at ACE 2019 Annual Meeting

Principal Ryan Tubman and Head of Analytics Mike Roy present a poster at the annual meeting of the American College of Epidemiology

Conferences

11th Annual Next Generation Dx Summit

Principal Charles Matthews will be attending to engage in collaboration and networking

Conferences

Solving for the Future: Building Strategy through Forecasting

Key guiding principles for effective forecasting, common pitfalls, and how to use a forecast to develop better strategy

White Papers

Landscape of Innovation (BIO 2019)

Presented at the 2019 BIO International Convention in Philadelphia, this talk by Sam Ulin, Managing Director, examines the drivers of value for innovators, with a focus on the technologies and applications that attracted significant funding in 2018

White Papers

2019 BIO International Convention

At BIO International Convention in Philadelphia on June 3, 2019, Managing Director Sam Ulin will give lead the Super Session talk, "What’s Next: The Landscape of Innovation in 2019 and Beyond"

Conferences

Rare Disease Genetic Testing Support Programs

As genetic testing becomes more accessible, how are companies incorporating these technologies into their strategy?

Quick Takes

The Role of RWE in Supplemental or Conditional Approvals

RWE has become increasingly important in supporting supplemental or conditional drug approvals. Where is the space headed?

Quick Takes

13th Annual BIO-EUROPE Spring

Managing Directors Phil Kenner and Seth Berman will be attending this springtime partnering conference

Conferences

Trump/HHS Proposal to Change Federal Drug Rebates

What are the implications of the DHHS' new plan to overhaul prescription drug rebates for federal beneficiaries?

Quick Takes

37th Annual J.P. Morgan Healthcare Conference

The ClearView leadership team will be attending this industry-leading healthcare investment symposium

Conferences

Developing a Go-To-Market Strategy for Your Lead Asset

Launching a new therapy is a complex endeavor. We will review the various activities key to a successful drug launch.

White Papers

Building Flexibility into Your R&D Strategy

How can flexibility in clinical development can be incorporated at various points along an asset’s life cycle

White Papers

Aligning Access Investments to Today’s Payer Realities

Navigating new challenges of market access and reimbursement for new pharmaceuticals in today's market

White Papers

The Evolving Market Access Landscape for Orphan Drugs

Recent changes in the orphan drug market access landscape and implications for pharmaceutical developers

White Papers

Greater Value Creation with Digital Health

Distinct ways that medtech companies can incorporate digital health technologies into their portfolios

White Papers

Investing in Rare Disease Patient Advocacy Groups

Investing early in PAGs’ success is a sound strategic move that may increase a company’s chances of success by forming a collaboration that enhances patient access

White Papers

The Challenges of Gene Therapy

Building a well thought-out plan to establish evidence of safety and of clinical utility to establish trust in a new platform

White Papers

Opportunity Assessment Through the In-Licensor’s Lens

Technical and transactional assessments required to identify the right type of partnership for a biotech’s asset or platform and overall business needs

White Papers

To Partner or Not to Partner: Growing Up Biotech Series

This second installment of our “Growing Up Biotech” series identifies the key factors around a pivotal question posed when launching your product: to partner or not to partner?

White Papers

Taking the Long View: Growing Up Biotech Series

In the first white paper in our series “Growing Up Biotech”, we discuss the importance of communicating a compelling product story early in a biotech’s development.

White Papers

Engaging Patient Advocacy Groups: A Key Piece of the Puzzle

PAGs play an increasingly important role in the drug development and regulatory process. Companies that truly want to be patient-centered should engage these groups early, often, and enthusiastically.

White Papers

IO’s Impact On Strategic Decision-Making In The Broader Oncology Landscape

In this article published in In Vivo, we review key strategic considerations across clinical development, market access, and post-launch commercialization important for oncology drug development.

White Papers

Orphan Diseases: Expansive Opportunity and Unique Challenges

What are the clear areas of opportunity and the unique challenges associated with orphan disease drug development to help companies be best prepared to succeed in this exciting, but nuanced, space?

White Papers

Companion Diagnostics: Strategies to Optimize Performance in the Era of Precision Medicine

Informed drug development in an era of “precision medicine” requires a clear understanding of the risks and benefits that accompany the pursuit of companion diagnostics, a difficult objective given the complexity and rapid evolution of the field.

White Papers

The Breakthrough Therapy Designation

What are the key advantages and disadvantages for a biopharmaceutical company to consider prior to pursuing the breakthrough therapy pathway?

White Papers